publications
Home >
연구실적

연구실적

논문

  1. DE Kim, HJ Oh, HJ Kim, YB Kim, ST Kim, H Yim* (2025)  Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma. Biomed Pharmacother 182:117796. doi: 10.1016/j.biopha.2024.117796.

  2. HJ Oh, AB Imam-Aliagan, YB Kim, HJ Kim, IA Izaguirre, CK Sung*, H Yim*. (2024) Clinical applications of circulating biomarkers in non-small cell lung cancer. Front Cell Dev Biol.12:1449232. doi: 10.3389/fcell.2024.1449232.

  3. Ampudia-Mesias E, Cameron CS, Yoo E, Kelly M, Anderson SM, Manning R, Abrahante Lloréns JE, Moertel CL, Yim H, Odde DJ, Saydam N, Saydam O. (2024) The OTX2 Gene Induces Tumor Growth and Triggers Leptomeningeal Metastasis by Regulating the mTORC2 Signaling Pathway in Group 3 Medulloblastomas. Int J Mol Sci 25(8):4416.  doi: 10.3390/ijms25084416. 

  4. R Xu, YJ Lee, CH Kim, GH Min, YB Kim, JW Park, DH Kim, JH Kim, H Yim* (2023) Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-assoicated macrophages to promote immune escape and metastasis, amplified by IFITM1. J. Exp. Clin. Cancer Res. 42(1):302. doi: 10.1186/s13046-023-02872-1.
  5. DE Kim, SB Shin, CH Kim,  YB Kim, HJ Oh,  H Yim* (2023) PLK1-mediated phosphorylation of beta-catenin enhances its stability and transcriptional activity for extracellular matrix remodeling in metastatic NSCLC. Theranostics 13 (3): 1198-1216. doi: 10.7150/thno.79318.
  6. DH Kim, NY Song, H Yim* (2023) Targeting dysregulated lipid metabolism in the tumor microenvironment (2023) Arch. Pharm. Res. doi: 10.1007/s12272-023-01473-y.
  7. DE Kim, HE Byeon, DH Kim, SG Kim*, H Yim* (2023) Plk2-mediated phosphorylation and translocalization of Nrf2 activates anti-inflammation through p53/Plk2/p21cip1 signaling in acute kidney injury. Cell Biol. Toxicol. 39(4):1509-1529. doi: 10.1007/s10565-022-09741-1.
  8. CH Kim, DE Kim, DH Kim, GH Min, JW Park, YB Kim, CK Sung, H Yim* (2022) Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis. Exp Mol Med. 54(4):414-425. doi: 10.1038/s12276-022-00750-y. 
  9. HR Hang, SB Shin, CH Kim, JY Won, R Xu, DE Kim, H Yim* (2021) PLK1/ vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. Cell Death Differ. 28: 2745-2764.

  10. SB Shin, DH Kim, DE Kim, MBD Aldonza, Y Kim, H Yim* (2021) Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters. Cancers 13(17): 4413, doi: 10.3390/cancers13174413. 

  11. SB Shin, HR Jang, R Xu, JY Won, H Yim* (2020) Active PLK1-driven metastasis is amplified by TGF-β signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene 39(4):767-785.
  12. CK Sung, H Yim* (2020) CRISPR-mediated promoter de/methylation technologies for gene regulation. Arch. Pharm. Res. 43: 705-713.
  13. SB Shin, CH Kim, HR Jang, H Yim* (2020) Combination of inhibitors of USP7 and PLK1 has a strong synergism against paclitaxel resistance. Int. J. Mol. Sci. 21 (22): 8629.
  14. R Xu, JY Won, CH Kim, DE Kim, H Yim* (2019) Roles of the phosphorylation of transcriptional factors in epithelial-mesenchymal transition. J. Oncol. 2019:5810465. doi: 10.1155/2019/5810465.
  15. SB Shin, SU Woo, H Yim* (2019) Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer. Ther. Adv. Med. Oncol. 11:1758835919846375. doi: 10.1177/1758835919846375.
  16. MS Joo, SB Shin, EJ Kim, JH Koo, H Yim*, SG Kim* (2019) Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21cip1. FASEB J. 33(7): 7953-7969. 
  17. HS Chae, R Xu, JY Won, YW Chin, H Yim* (2019) Molecular targets of genistein and its related flavonoids to exert anticancer effects. Int. J. Mol. Sci. 20 (10) pii: E2420.
  18. SU Woo, HR Jang, YW Chin, H Yim* (2019) 7-O-methylwogonin from Scutellaria baicalensis disturbs mitotic progression by inhibiting Plk1 activity in Hep3B cells. Planta Med. 85(3) 217-224.
  19. H Kim, H Yim* (2018) 53BP1: A guardian for centrosomal integrity. Frontiers in Bioscience-Landmark 23(1) 1-12.
  20. SB Shin, SU Woo, Y-W Chin, Y-J Jang, H Yim* (2017) Sensitivity of TP53-mutated cancer cells to the phytoestrogen genistein is associated with direct inhibition of Plk1 activity. J. Cell. Physiol.​ 232(10) 2818-2828.
  21. MS Joo, JH Koo, SB Shin, H Yim, SG Kim (2017) Oligopeptide competition assay for phosphorylation site determination. J. Vis. Exp. 123, Doi: 10.3791/55708.
  22. SB Shin, SU Woo, YJ Lee, H Yim* (2017) Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy. Anticancer Res. 37 (3) 1177-1183. 
  23. CK Sung, H Yim* (2017) Roles of SALL2 in tumorigenesis. Arch. Pharm. Res. 40 (2) 146-151.
  24. H Yim*, SB Shin, SU Woo, PC Lee, RL Erikson (2017) Plk1-mediated stabilization of 53BP1 through USP7 regulates centrosome positioning to maintain bipolarity. Oncogene 36, 966-978.
  25. YM Han, SU Woo, MS Choi, YN Park, SH Kim, H Yim*, HH Yoo* (2016) Antiinflammatory and analgesic effects of Eurycoma longifolia extracts. Arch. Pharm. Res. 39(3) 421-8.
  26. SB Shin, SU Woo, H Yim*(2015) Differential cellular effects of Plk1 inhibitors targeting the ATP-binding domain or polo-box domain. J. Cell. Physiol. 230(12)3057-67.
  27. CK Sung, H Yim* (2015) The tumor suppressor protein p150(Sal2) in carcinogenesis. Tumor Biology 36(2): 489-94.
  28. IS Hwang, SU Woo, JW Park, SK Lee, H Yim* (2014) Two nuclear export signals of Cdc6 are differentially associated with CDK-mediated phosphorylation residues for cytoplasmic translocation. Biochimca et Biophysica Acta-Mol. Cell Res. 1843 (2): 223-33.
  29. H Yim* and RL Erikson (2014) Plk1-targeted therapies in TP53- or RAS-mutated cancer. Mutation Research Review in Mutation Research 761,31-39.
  30. SJ Lee, JW Hwang, H Yim, HJ Yim, SU Woo, SJ Sur, JJ Hyun, SW Jung, JS Koo, JH Kim, YS Seo, JE Yeon, SW Lee, KS Byun, SJ Um (2014) Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. J. Gastroenterol. Hepatol. 29(6) 1299-307.
  31. L Liu, H Yim, JH Choi, ST Kim, Y Jin, SK Lee (2014) ATM kinase promotes both caspase-8 and caspase-9 activation during TNF-a-induced apoptosis of HeLa cells. FEBS Letters 588(6):929-35.
  32. HE Yim, H Yim, ES Bae, SU Woo, KH Yoo (2014) Predictive value of urinary and serum biomarkers in yound children with febrile urinary tract infections. Pediatric Nephrology 29(11):2181-9.
  33. CK Sung, H Yim, E Andrews, TL Benjamin (2014) A mouse polyomavirus-encoded microRNA targets the cellular apoptosis pathway through Smad2 inhibition. Virology 468-470:57-62.
  34. H Yim* (2013) Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer drugs 24(10):999-1006.
  35. HJ Cha, H Yim* (2013) The accumulation of DNA repair defects is the molecular origin of carcinogenesis. Tumor Biology 34(6):3293-302.
  36. H Yim*, JW Park, SU Woo, ST Kim, L Liu, CH Lee, SK Lee (2013) Phosphorylation of Cdc6 at serine 74, but not at serine 106, drives translocation of Cdc6 to the cytoplasm. J. Cell. Physiol. 228(6): 1221.
  37. Chang K. Sung*, Hyungshin Yim*, Hongcang Gu, Dawei Li, Erik Andrews, Sekhar Duraisamy, Cheng Li, Ronny Drapkinand Thomas L. Benjamin. (2012) The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC. PLoS One 7(9): e46486. *Co-first author

  38. Xiao-Xi Guo , Hanna Kim, Yang Li, Hyungshin Yim, Seung Ki Lee, Ying-Hua Jin. (2011) Cdk2 acts upstream of mitochondrial permeability transition during paclitaxel-induced apoptosis. Protein Cell 2(7):543-53.

  39. Hyungshin Yim, Chang K. Sung, John You, Tian You, and Thomas L. Benjamin. (2011) NeK1 and TAZ models of polycystic kidney disease are linked through phosphorylation and ubiquitination. J. Am. Soc. Nephrol. 22(5) 832-837.
  40. Hyungshin Yim and Raymond L. Erikson. (2011) Regulation of the final stage of mitosis by com-ponents of the pre-replicative comples and a polo kinase. Cell Cycle 10 (9). 1374-1377.
  41. Hongcang Gu, Dawei Li, Chang K. Sung, Hyungshin Yim, Philip Troke and Thomas Benjamin. (2011) DNA-binding properties of the transcription factor and putative tumor suppressor p150sal2. Biochimica et Biophysica Acta. 1809 (4-6), 276-283.
  42. Chang K. Sung, Jean Dahl, Hyungshin Yim, Scott Rodig, Thomas L. Benjamin. (2011) Transcrip-tional and post-translational regulation of the quiescence factor and putative tumor suppressor p150Sal2. FASEB J. 25(4): 1275-83.
  43. Hyungshin Yim* and Raymond L. Erikson*. (2010) Cdc6. A Mitotic Substrate and Partner of PIK1, Regulates Chromosomal Segregation Mediated by Cdk1-separase. Proc. Natl. Acad. Sci. USA 107(46):19742-7. *Co-corresponding author
  44. Linhua Liu, Jae Hyuk Choi, Hyungshin Yim, joon-seok Choi, Byoung Duck Park, Seung Ju Cho, Seung Ki Lee (2009) ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induces S-phase arrest of HeLa cells. Int J. of Biochem. Cell Biol. 41 (6):1410-20.
  45. Hyungshin Yim* and Raymond L. Erikson (2009) Polo-like kinase-1 depletion induces DNA damage in early S prior to caspase activation. Mol. Cell. Biol. 29 (10): 2609-2621. *Correspond-ing author
  46. Joon-Seok Choi, Soona Shin, Ying Hua Jin, Hyungshin Yim, Kyo-Tan Koo, Kwang-Hoon Chun, You-Take Oh, Won Hee Lee, Seung ki Lee. (2007) Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis 12 (7): 1229-41.
  47. Young-Mi Ham, Jin-Hee Lim, Joon-Seok Choi, Byoung-Duck Park, Hyungshin Yim, Seung-Ki Lee. (2006) Ginsenoside-RH2 induces mitochondrial depolarization that is associated with ROS-and Ca2+-mediated JNK1 activation during apoptosis. J. Pharmacology and Experimental Therapeutics. 319 (3): 1276-1285.
  48. Hyungshin Yim, In Seon Hwang, Joon Seok Choi, Kwang Hoon Chun, Ying Hua Jin, Young-Mi Ham, Kwang Youl Lee, and Seung Ki Lee (2006) Caspase-3-cleavage of Cdc6 induces ATM/ATR kinase-mediated apoptosis of HeLa cells. J. Cell Biol. 174 (1): 77-88.
  49. Yong Woong Kim, Kyo Tan Koo, Joon Seok Choi, Ying Hua Jin, Hyungshin Yim, You Take Oh, and Seong Ki Lee. (2005) Analysis of cylcin-dependent kinase2-regulated phosphorylation of Stath-min in etoposide-induced apoptotic HeLa cells by two-dimensional electrophoresis and mass spectrometry. J. Health Sci., 51: 224-232.
  50. Hyungshin Yim, Ying Hua Jin, Byoung Duck Park, Hye Jin Choi, and Seung Ki Lee (2003) Caspase-3-mediated Cleavage of Cdc6 Induces Nuclear Localization of p49-truncated Cdc6 and Apoptosis. Mol. Biol. Cell, 14 (1): 4250-4259.
  51. Ying Hua Jin, Hyungshin Yim, Jeong Hill Park, and Seung Ki Lee. (2003) Cdk2 activity is associ-ated with depolarization of mitochondrial membrane potential during apoptosis. Biochem. Biophy. Res. Comm., 305 (4): 974-980.
  52. Hyungshin Yim, Yong Hee Lee, Chul Hoon Lee, and Seung Ki Lee. (1999) Emodin, an Anthraqui-none Derivative Isolated from the Rizomes of Rheum pheum palmatum, Selectively Inhibits the Activity of Casein Kinase II as a Competitive Inhibitor. Planta Medica 65 (1): 9-13.

특허

  1. 임형신, 장해란 (2023.09.27) 비멘틴  발현 억제용 shRNA를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물. 대한민국특허청. 특허등록번호 #10-2585460.
  2. 임형신, 장해란 (2023.03.15) 비멘틴 돌연변이체 또는 이를 발현하는 벡터를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물. 대한민국특허청. 특허등록번호 #10-2511660.
  3. 임형신, 장해란, 신솔비 (2022.11.07) TSG6 억제제를 포함하는 전이성 고형암 치료용 조성물. 대한민국특허청. 특허등록번호 #10-2466691.
  4. 임형신, 신솔비 (2022.04.21) 항암제 병용 투여용 약학 조성물. 대한민국특허청. 특허등록번호 #10-2390586.
  5. 임형신, 신솔비 (2021.01.25) 전이성 암 치료용 조성물. 대한민국특허청. 특허등록번호 #10-2209537.
  6. 임형신, 신솔비 (2020.06.15) 53BP1의 신규한 용도. 대한민국특허청. 특허등록번호 #10-2125005.
  7. 임형신, 우상욱, 진영원 (2016.11.16) p53 돌연변이성 고형암 및 탁솔 내성 고형암 치료제로서의 제니스테인의 항암제 용도. 대한민국 특허청. 특허등록번호 # 10-1678791.
  8. 이승기, 임형신(2009.04.21)ATM/ATR을 이용한 세포사멸 조절제 스크리닝 방법. 대한민국 특허청. 특허등록번호#10-0895256.
  9. 이승기, 임형신(2008.10.16) Cdc6돌연변이 단백질을 포함하는 세포 사멸 억제제 및 Cdc6 결실 단백질을 포함하는 세포 사멸 유도제. 대한민국 특허청. 특허등록번호 #10-0864870.
  10. 이승기, 임형신 (2006.03.22) Cdc6의 일부가 결실된 단백질을 함유하는 세포 사멸 유도제. 대한민국 특허청. 특허 등록 번호 #10-0565699.
PC버전 보기
관련사이트 바로가기
15588 경기도 안산시 상록구 한양대학로 55 한양대학교 약학대학(302호) TEL. 031-400-5810 FAX. 031-400-5958 E-mail. hsyim@hanyang.ac.kr

Copyright (c) 2016 Hanyang University. All Rights Reserved.

TOP
 
사이트맵 닫기